Skip to main content
OpenTrials
Completed

NCT Number: NCT03710187

HCT+F vs. HCT Alone in Critically Ill Medical Septic Shock Patients

This study will be conducted as a single-center, prospective, open-label, randomized trial that will evaluate adult patients admitted with septic shock to the medical critical care unit (MCC). The objective of the study is to determine if the use of hydrocortisone plus fludrocortisone is associated with a faster resolution of shock (defined as 24 hours vasopressor free) when compared to the use of hydrocortisone alone in medical, critically ill septic shock patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

University of Tennessee Medical Center

Knoxville, Tennessee, 37920, United States

About this study

For three consecutive months, side 1 of the medical critical care unit (MCC1) will receive hydrocortisone alone and side 2 (MCC2) will receive the combination of hydrocortisone and fludrocortisone. After the initial three months, this will be flipped and patients admitted to MCC1 will receive the combination while patients in MCC2 will receive hydrocortisone alone for three consecutive months. This change in group assignments will occur to account for the difference in number of beds between MCC1 and MCC2, and to minimize the potential differences in patient acuity by location.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Critically ill medical patients requiring addition of stress dose steroid therapy (hydrocortisone) in addition to pressors for septic shock management during ICU stay
  • Fludrocortisone administered within 24 hours after initiation of hydrocortisone if in combination therapy group

Exclusion criteria

  • Use of fludrocortisone and/or hydrocortisone for any reason other than septic shock management during ICU stay
  • Fludrocortisone/hydrocortisone initiated by any service other than critical care medicine
  • Prior use of fludrocortisone/hydrocortisone at time of admission (home or outside facility)
  • Patients not appropriate for study inclusion as determined by provider discretion
  • Patients receiving steroid therapy not in accordance with assigned group per location (MCC1 or MCC2)
  • Patients re-admitted to the MCC during the same admission and restarted on vasopressor therapy will be noted during data collection and only the initial admission will be included for analysis
  • Any patient receiving greater than one dose of hydrocortisone 100 mg
  • Physical or medical contraindication to receiving PO or PER FT (per feeding tube) fludrocortisone

Treatment and study plan

Hydrocortisone

Drug

Hydrocortisone 50 mg IV Q6h

Primary outcomes

  1. Time to Resolution of Shock

    Time frame: Up to one week

    Hours for patient to achieve 24 hours vasopressor free

Sponsors and collaborators

Lead sponsor

University of Tennessee Medical Center

Other

Registry information

Official study title

Hydrocortisone and Fludrocortisone Versus Hydrocortisone Alone in Critically Ill Medical Patients With Septic Shock

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Oct 18, 2018
Registry last updated
May 20, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.